InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,447.87
(
-0.31%
)
US TECH 100
18,978.00
(
-1.19%
)
Dow Jones
39,411.21
(
0.67%
)
Brent Oil
85.21
(
-0.08%
)
Bitcoin
61,357.38
(
1.81%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119911
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Pre_Clinical post# 4674

Thursday, 08/16/2007 5:14:42 PM

Thursday, August 16, 2007 5:14:42 PM

Post# of 19309
>I would refer you to the Kybersept study which shows that AT3 failed in its clinical trial and showed an additional risk of hemorrhage<

For what it’s worth, I give the ATryn program in DIC/sepsis program a 70% chance of success. The scientific rationale is laid out in several posts in the ReadMeFirst, which includes analysis of the Kybersept study.

--
Most readers here are wise to your agenda, IMO. True, you were able to fool the more gullible posters (e.g. quantumdot), but most of us saw through your game rather quickly.

Out.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up